{"id":45386,"date":"2025-10-31T11:43:31","date_gmt":"2025-10-31T03:43:31","guid":{"rendered":"https:\/\/flcube.com\/?p=45386"},"modified":"2025-10-31T11:43:32","modified_gmt":"2025-10-31T03:43:32","slug":"takeda-reports-3-9-yoy-revenue-decline-in-h1-2025-citing-neuroscience-slump-and-fx-headwinds","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45386","title":{"rendered":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) released its first\u2011half 2025 financial results today, showing global revenues of <strong>\u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion)<\/strong>, a <strong>3.9\u202f% year\u2011on\u2011year (YoY) slowdown<\/strong> in constant currency terms. The decline was largely driven by a dip in the <strong>Neuroscience<\/strong> segment and unfavorable foreign\u2011exchange rates.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\"><strong>Financial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1\u202f2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Revenue<\/strong><\/td><td>\u00a52,219.5\u202fbillion<\/td><td>\u20133.9\u202f%<\/td><\/tr><tr><td><strong>Core Revenue Outlook<\/strong><\/td><td>Flat<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Core Operating Profit<\/strong><\/td><td>Flat<\/td><td>\u2013<\/td><\/tr><tr><td><strong>EPS Guidance<\/strong><\/td><td>Flat<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Top\u2011Seller<\/strong><\/td><td>Entyvio (vedolizumab)<\/td><td>+5.1\u202f%<\/td><\/tr><tr><td><strong>Weakest Segment<\/strong><\/td><td>Vyvanse\/Elvanse (lisdexamfetamine)<\/td><td>\u201345.6\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuroscience<\/strong> \u2013 Sales fell <strong>\u2248\u202f7\u202f%<\/strong> after a 12\u2011month decline in key products.<\/li>\n\n\n\n<li><strong>Foreign\u2011Exchange Impact<\/strong> \u2013 A stronger yen and weaker USD\/EUR contributed <strong>\u2248\u202f4\u202f%<\/strong> of the revenue slide.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-performance\"><strong>Geographic Performance<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Revenue (\u00a5\u202fbn)<\/th><th>YoY Growth<\/th><\/tr><\/thead><tbody><tr><td>Japan<\/td><td>219.1<\/td><td>+1.3\u202f%<\/td><\/tr><tr><td>United States<\/td><td>1,091.9<\/td><td>\u20137.9\u202f%<\/td><\/tr><tr><td>Europe &amp; Canada<\/td><td>535.2<\/td><td>+0.8\u202f%<\/td><\/tr><tr><td>Latin America<\/td><td>118.5<\/td><td>\u20135.4\u202f%<\/td><\/tr><tr><td>China<\/td><td>92.7<\/td><td>+7.5\u202f%<\/td><\/tr><tr><td>Asia Ex\u2011Japan &amp; China<\/td><td>47.8<\/td><td>\u20130.5\u202f%<\/td><\/tr><tr><td>Russia\/CIS<\/td><td>43.2<\/td><td>\u20132.3\u202f%<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td>71.2<\/td><td>+0.7\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>China<\/strong> emerges as the only region with double\u2011digit growth, expanding 7.5\u202f% YoY to <strong>\u00a592.7\u202fbillion (USD\u202f608\u202fmillion)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-management-commentary\"><strong>Management Commentary<\/strong><\/h2>\n\n\n\n<p>CEO <strong>Christophe Weber<\/strong> said the results were <strong>\u201cconsistent with our expectations\u201d<\/strong> in a year of \u201ctransition to a new phase focusing on new product launches.\u201d Takeda\u2019s full\u2011year guidance was revised to reflect a <strong>flat core revenue outlook<\/strong> and <strong>low\u2011single\u2011digit declines<\/strong> in core operating profit and earnings per share.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-performance\"><strong>Key Product Performance<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Entyvio (vedolizumab)<\/strong> \u2013 Leading revenue driver, growing <strong>5.1\u202f%<\/strong> to <strong>\u00a5479.2\u202fbillion<\/strong>.<\/li>\n\n\n\n<li><strong>Vyvanse\/Elvanse (lisdexamfetamine)<\/strong> \u2013 Subject to generic erosion, sales fell <strong>45.6\u202f%<\/strong> to <strong>\u00a5106.6\u202fbillion<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/qr2025_q2_qfr_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of qr2025_q2_qfr_en.\"><\/object><a id=\"wp-block-file--media-03376ddc-8267-4ccd-b907-1022e92b0292\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/qr2025_q2_qfr_en.pdf\">qr2025_q2_qfr_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/qr2025_q2_qfr_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-03376ddc-8267-4ccd-b907-1022e92b0292\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[874,345,1141],"class_list":["post-45386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-nyse-tak","tag-takeda","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T03:43:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T03:43:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds\",\"datePublished\":\"2025-10-31T03:43:31+00:00\",\"dateModified\":\"2025-10-31T03:43:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3105.webp\",\"keywords\":[\"NYSE: TAK\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45386#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45386\",\"name\":\"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3105.webp\",\"datePublished\":\"2025-10-31T03:43:31+00:00\",\"dateModified\":\"2025-10-31T03:43:32+00:00\",\"description\":\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3105.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45386","og_locale":"en_US","og_type":"article","og_title":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds","og_description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.","og_url":"https:\/\/flcube.com\/?p=45386","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T03:43:31+00:00","article_modified_time":"2025-10-31T03:43:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds","datePublished":"2025-10-31T03:43:31+00:00","dateModified":"2025-10-31T03:43:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45386"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","keywords":["NYSE: TAK","Takeda","TYO: 4502"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45386#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45386","url":"https:\/\/flcube.com\/?p=45386","name":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45386#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","datePublished":"2025-10-31T03:43:31+00:00","dateModified":"2025-10-31T03:43:32+00:00","description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first\u2011half 2025 financial results today, showing global revenues of \u00a52,219.5\u202fbillion (USD\u202f14.57\u202fbillion), a 3.9\u202f% year\u2011on\u2011year (YoY) slowdown in constant currency terms. The decline was largely driven by a dip in the Neuroscience segment and unfavorable foreign\u2011exchange rates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45386#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","width":1080,"height":608,"caption":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Reports 3.9% YoY Revenue Decline in H1\u202f2025, Citing Neuroscience Slump and FX Headwinds"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45386"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45386\/revisions"}],"predecessor-version":[{"id":45391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45386\/revisions\/45391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45388"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}